contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


modulight-to-publish-its-financial-statements-bulletin-for-january-december-2025-on-february-20-2026

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Modulight operates in the technology industry. The company designs, markets, and produces biomedical laser products used in oncology, genetics, and ophthalmology. The customers primarily consist of hospitals and corporate customers operating in medical technology. In addition to the main business, various value-added services are also offered. Their main market is the US.

Siltanen interviewed Modulight CEO Seppo Orsila regarding Q4                    Inderes              Modulight Q4'25: Oikeaan suuntaan - Inderes    Aika: 20.02.2026 klo 14.50 Modulight jatkoi hyvää kehitystä loppuvuonna, kun liikevaihto kasvoi ennätyksellisen voimakkaasti.                             Topics: 00:00 Introduction  00:13 Highlights of the end of the year and the full year 2025  01:13 Revenue from the PPT business model  03:47 Successes and challenges of Visudyne treatment  06:29 Local manufacturing in the United States  07:56 Impact of geopolitics on production  10:48 Outlook and focus areas for the current year  12:55 Successes and challenges of the past strategy period  Here is the release regarding the results:  Key highlights in October–December 2025  Projects in the R&D pipeline progressed – PPT is in use in 80 hospitals, and patient recruitment for clinical trials has progressed slightly faster than expected Free cash flow from operations was -538 (-2,513) thousand euros, improving by 79% Revenue was 1,736 (1,431) thousand euros EBITDA was 641 (-1,023) thousand euros EBITDA margin (EBITDA-%) was 37.0 (-71.5) % of revenue Operating result (EBIT) was -787 (-2,204) thousand euros Operating margin (EBIT-%) was -45.4 (-154.0) % of revenue Earnings per share was -0.02 (-0.02) euros  Key highlights in 2025  Total number of R&D projects at the end of the year was 33 (30) Revenue was 7,069 (4,095) thousand euros EBITDA was -168 (-4,836) thousand euros EBITDA margin (EBITDA-%) was -2.4 (-118.1) % of revenue Operating result (EBIT) was -4,648 (-8,337) thousand euros Operating margin (EBIT-%) was -65.8 (-203.6) % of revenue Earnings per share was -0.11 (-0.15) euros The company’s Board of Directors proposes that no dividend be paid for the 2025 financial year    Outlook for 2026  Most of Modulight’s customer projects are various types of early-stage development projects. Modulight’s own products are sold in these projects. In line with its strategy, Modulight is also transitioning from payments based on equipment deliveries to a new payment model based on treatment sessions (PPT business model). The progress of individual projects is difficult to predict, and macroeconomic and geopolitical uncertainty continue to affect market development. For these reasons, forecasting revenue is challenging, and Modulight does not provide guidance for revenue or profitability for 2026. Seppo Orsila, CEO  Revenue and profitability continued to improve in line with the strategy. The acceleration in customer activity that began in the summer continued until the turn of the year, and the events in January, which are traditionally important to us, were exceptionally successful. Cancer and eye treatments are progressing well, and more opportunities for our products have also been found in other high-value applications. A few of our customers have moved into small-scale production, and the “ramp-up” is progressing, albeit slowly. EBITDA developed in the right direction during the year, reaching 37% in the fourth quarter. We consider the development of EBITDA to be good, even though the level is not yet satisfactory. Revenue in the fourth quarter was 1.7 million euros, which is 21% more than in the corresponding period of 2024. Full-year revenue grew by 73% compared to the previous year. The diversification of the customer portfolio, as well as the progress and increase in the number of projects, supported this development. I am pleased that our business has now grown for 5 consecutive quarters. At the same time, we achieved the highest annual percentage growth in our history and significantly improved our profitability. Our own production facility is an increasingly important competitive factor in the current world situation. This is reflected in a positive momentum both in discussions with pharmaceutical companies and in negotiations for other customer relationships based on high-value applications. Our technology and unique production capabilities located in Europe have clearly led our customers to trust us in their development choices for future products. Most of our projects are such that the customer effectively commits to us long-term as their sole technology partner. The United States remains the company’s main focus, and our operations there are developing strongly. We have continued to develop local manufacturing. We see opportunities especially in flow cytometry, microscopy, the semiconductor industry, quantum technology, and the defense industry. In all of these, we have globally significant companies as customers. Our EBITDA rose to 37% during the quarter and improved by 163%, amounting to 0.6 (-1.0) million euros. Correspondingly, the operating result improved by 64%, amounting to -0.8 (-2.2) million euros. Looking at the figures for both this quarter and the full year, it can be observed that revenue growth has improved the result. We have analyzed the profitability of our more mature products and found that the gross margin is developing in the right direction. This is, on one hand, a testament to the efficiency of our investments, but on the other hand, it also confirms our understanding of the business’s scalability. Profitability has also been significantly improved by the increased synergy between different customer accounts and products, as the same platforms are used in an increasing number of customer accounts, and the amount of required configuration is decreasing and becoming more streamlined. During Q3, we noted that the PPT business now generates more from certain products than what the old business model would generate even if we resold the entire installed base of equipment every year. The positive development continued in Q4, and as a result, our PPT revenue ended up with strong triple-digit annual growth compared to 2024. In absolute terms, our PPT revenue exceeded one million euros in 2025. This is another new milestone in the development of our new business model, although still a small figure in absolute terms. More significant than the numbers in the PPT area, however, are the signals of several of our customers’ willingness to transition to our technology, the scaling plans of existing customers, and the partially faster-than-expected development of clinical trials compared to a year ago. The goal of our projects is the commercialization of our own products. Our R&D pipeline grew to 33 projects. The amount of positive customer feedback has continued to grow, and we have also gained new business opportunities after customers recommended us to other companies. There are now 80 treatment points in the PPT business, and we are approaching the milestone of 1,000 treated eye patients this year. The goal of our 2023–2025 strategy period was a return to strong and profitable growth. The record 73% revenue growth in 2025 can be considered a success, but in terms of profitability, we are not at the targeted level, although we have progressed in the right direction. Our growth strategy is headed in the right direction, but we still need a little more time. We have streamlined our operations and paid special attention to the sufficiency of our cash reserves. Our goal is to continue positive development in 2026. The company has earlier today announced an updated strategy and financial targets.                    Inderes              Modulight: Ennätysvuosi liikevaihdon kasvussa - Inderes    Modulight Oyj | Yhtiötiedote | 20.02.2026 klo 11:00:00 EETTämä tiedote on tiivistelmä Modulightin tilinpäätöstiedotteesta 2025. Koko raportti on tämän pörssitiedotteen liitteenä pdf-tiedostona...                             Here are the robot’s comments:                  Inderes              Robokommentti Modulightin Q4-tuloksesta - Inderes    Modulightin Q4-tulos oli kaksijakoinen: liikevaihto 1,7 MEUR jäi selvästi 2,15 MEUR:n ennusteestamme, mutta käyttökatetason kehitys yllätti positiivisesti kustannuskurin ja PPT-mallin korkeakatteisen liikevaihdon ansiosta. Kassan polttotahti hidastui...                             And the release regarding the strategy update   Modulight is updating its strategy and long-term financial targets, which extend to the end of the 2027 financial year. The company reiterates its financial targets regarding revenue and EBITDA, aiming for strong annual revenue growth and a return to strong profitability. In addition, the goal is to achieve positive cash flow by the end of the strategy period. The company’s dividend policy remains unchanged.                    Inderes              Sisäpiiritieto: Modulight Oyj päivittää strategiaansa ja antaa uudet...    Modulight Oyj | Sisäpiiritieto | 20.02.2026 klo 10:59:00 EETModulight päivittää strategiaansa ja pitkän aikavälin taloudellisia tavoitteitaan, jotka ulottuvat tilikauden 2027 loppuun saakka....

Tampere is a laser valley                   Tekniikka&Talous – 18 Feb 26              Maailman tarkimpia lasereita valmistava suomalaisyritys 100 % vuosikasvussa –...    Tamperelainen puolijohdelasereihin erikoistunut Vexlum valmistaa tuotteita, jotka ovat vähintään miljardi kertaa tarkempia kuin monet muihin käyttötarkoituksiin käyttökelpoiset laserlaitteet. Yhtiö haluaa olla 2030-luvulla 100–200 miljoonan...

Here are Antti’s pre-result comments as Modulight reports its results on Friday, February 20.  We expect the company’s revenue to have continued its growth and the loss to have narrowed from the comparison period, although the operating result still remains clearly negative. In the report, our attention will be focused particularly on the development of recurring PPT revenue, cost savings from change negotiations, and cash sufficiency.                   Inderes              Modulight Q4'25 -ennakko: Loppusilaus kasvuvuodelle - Inderes    Vuosi 2025 on ollut yhtiölle parempi. Näkyvyys tulevaan on kuitenkin vähäinen.

Yeah, I have a prediction. Nothing particularly positive in store. Same as before, i.e., burning through cash.

It’s earnings day this Friday. Any predictions or thoughts on what’s in store?

Is patience starting to run out soon? The cash will last for almost two years.

There has been news coverage about quantum technology in recent days. These reports mentioned that the technology is constantly evolving and will enable a great deal across many industries. Quantum technology is expected to enter commercial use around the year 2030; I believe Modulight will be a stock market rocket by then at the latest.

Modulight

Modulight Corporation | Press Release | February 13, 2026 at 09:15:00 EETModulight Corporation will publish its financial statements bulletin for January–December 2025 on Friday, February 20...

<div class="mfn-header mfn-header-finland"><p>Modulight Corporation | Press Release | February 13, 2026 at 09:15:00 EET</p></div><div class="mfn-body"><p>Modulight Corporation will publish its financial statements bulletin for <strong>January–December 2025</strong> on <strong>Friday, February 20, 2026</strong>, approximately at <strong>11:00 a.m.</strong> EET. </p><p>Modulight's CEO Seppo Orsila will present the result in an English-language webcast, which will be held on <strong>February 20, 2026, at 12:00 p.m.</strong> EET. The registration and access to the webcast are available through the following link: <strong><a rel="noopener" href="https://modulight.zoom.us/webinar/register/WN_sieeVYahT7CaTM4S-Crtlg">https://modulight.zoom.us/webinar/register/WN_sieeVYahT7CaTM4S-Crtlg</a></strong></p><p>Questions can be submitted in writing through the webcast portal. CFO Anca Guina will also be present to answer questions. Presentation materials will be available before the start of the event on the company’s website at <strong><a rel="noopener" href="http://www.modulight.com/reports-presentations/">www.modulight.com/reports-presentations/</a></strong>.</p></div><div class="mfn-footer mfn-contacts mfn-94b966cad316"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p>CEO Seppo Orsila m. +358 40 830 4671<br>CFO Anca Guina m. +358 40&nbsp;830 4674<br>IR Ulla Haapanen m. +358 40 830 4676<br>Email: <a rel="noopener" href="mailto:ir@modulight.com">ir@modulight.com</a></p></div><div class="mfn-footer mfn-about mfn-f80935501c1c"><p><strong class="mfn-heading-1">Modulight in brief</strong></p><hr><p>Modulight Corporation is a biomedical laser company that designs and manufactures products for oncology, ophthalmology and genetics. The company also provides solutions for selected high value-add applications including quantum computing and digital press. The company’s products include medical devices, subsystems, software, cloud services and specialized semiconductors. Modulight’s products are used worldwide by many Fortune 500 companies, pharmaceutical companies, and well-known cancer centers and universities. Modulight was founded in 2000 and is headquartered in Tampere, Finland.</p><p>Follow&nbsp;Modulight: <a rel="noopener" href="https://modulight.com">modulight.com</a> | <a rel="noopener" href="https://twitter.com/modulight">X&nbsp;</a>|&nbsp;<a rel="noopener" href="https://www.linkedin.com/company/modulight/">LinkedIn</a> | <a rel="noopener" href="https://www.facebook.com/modulight.inc">Facebook</a>&nbsp;|&nbsp;<a rel="noopener" href="https://www.youtube.com/Modulight">YouTube</a>&nbsp;|&nbsp;<a rel="noopener" href="https://www.instagram.com/modulight.inc/">Instagram</a>&nbsp;| #killcancer #laserfamily</p></div>